OXYCODONE AND ACETAMINOPHEN (acetaminophen)
Oxycodone and Acetaminophen Tablets is indicated for the relief of moderate to moderately severe pain.
Details
- Status
- Prescription
- First Approved
- 1981-11-02
- Routes
- ORAL
- Dosage Forms
- TABLET, SOLUTION, CAPSULE
Companies
OXYCODONE AND ACETAMINOPHEN Approval History
What OXYCODONE AND ACETAMINOPHEN Treats
42 FDA approvalsOriginally approved for its first indication in 1981 . Covers 42 distinct patient populations.
- Other (42)
Other
(42 approvals)- • Approved indication (Nov 1981)
- • Approved indication (May 1989)
- • Approved indication (Jul 1996)
- • Approved indication (Oct 1997)
- • Approved indication (Jan 1998)
- • Approved indication (Jun 1998)Letter
- • Approved indication (Aug 1998)Label Letter
- • Approved indication (Dec 1998)Label Letter
- • Approved indication (Mar 1999)Letter
- • Approved indication (Mar 1999)Letter
- • Approved indication (Dec 1999)Label Letter
- • Approved indication (Oct 2000)Letter
- • Approved indication (Dec 2000)Letter
- • Approved indication (Sep 2003)
- • Approved indication (Jun 2004)
- • Approved indication (Dec 2005)
- • Approved indication (Apr 2006)
- • Approved indication (Apr 2006)
- • Approved indication (May 2006)
- • Approved indication (Sep 2006)
- • Approved indication (Nov 2007)
- • Approved indication (Oct 2008)
- • Approved indication (Apr 2012)
- • Approved indication (Jul 2012)
- • Approved indication (Apr 2013)
- • Approved indication (Jul 2013)
- • Approved indication (Jul 2013)
- • Approved indication (Dec 2013)
- • Approved indication (Aug 2014)Letter
- • Approved indication (Dec 2016)
- • Approved indication (Feb 2017)
- • Approved indication (Mar 2017)
- • Approved indication (Sep 2017)Letter
- • Approved indication (Dec 2017)
- • Approved indication (Feb 2018)
- • Approved indication (Mar 2018)
- • Approved indication (Jul 2018)
- • Approved indication (Nov 2018)Letter
- • Approved indication (Dec 2018)
- • Approved indication (Aug 2019)
- • Approved indication (Oct 2019)
- • Approved indication (Aug 2021)
OXYCODONE AND ACETAMINOPHEN Boxed Warning
WARNING Hepatotoxicity Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product....
WARNING Hepatotoxicity Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product.
Clinical Trial Registry
250 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05597878 | IRB00091354 P30CA012197, WFBCCC 01122 | Ph 2, Ph 3 | terminated | Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy |
| NCT07570173 | 1045-005 MK-1045-005, 2025-522267-15-00 | Ph 2, Ph 3 | recruiting | A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) |
| NCT05285813 | 2021-1124 NCI-2022-02215 | Ph 2 | terminated | A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure |
| NCT06186622 results posted | 18631 J2A-MC-GZPG | Ph 1 | completed | A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants |
| NCT03805932 results posted | 190042 19-C-0042 | Ph 1 | active not recruiting | Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia |
| NCT06009926 | NCI-2023-06404 NCI-2023-06404, STUDY00003544 | Ph 2 | active not recruiting | Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters |
| NCT04165096 results posted | 3475-01C MK-3475-01C, KEYMAKER-U01C | Ph 2 | completed | KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) |
| NCT05878015 | 23-000547 | Ph 4 | enrolling by invitation | A Study of Intravenous Acetaminophen for Small Bowel Obstruction |
| NCT07567924 | SIUT-ERC-2024/A-475 | Ph 4 | active not recruiting | Comparison Between Pregabalin and Acetaminophen for the Treatment of Post-Mastectomy Pain Syndrome |
| NCT04221477 REGENCY results posted | CA41705 2019-004034-42, 2023-503628-22-00 | Ph 3 | active not recruiting | A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis |
| NCT06043323 | 2023-0087 NCI-2023-07173 | Ph 2 | recruiting | A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma |
| NCT07571252 | 2603555595 | Ph 4 | not yet recruiting | Impact of Preemptive Analgesia on Postoperative Pain in Orthognathic Surgery |
| NCT06762600 | HRS-4729-101 | Ph 1 | completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects |
| NCT07525791 | NN9662-8158 U1111-1328-3457 | Ph 1 | recruiting | A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight |
| NCT07525219 | IRB00146434 | Ph 3 | not yet recruiting | Suzetrigine Frame Trial Comparing Suzetrigine and Acetaminophen |
| NCT07508241 | C6491010 MET097-25-106 | Ph 1 | recruiting | A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity |
| NCT03823534 | 28927 | Ph 3 | recruiting | Post-Op Pain Control for Prophylactic Intramedullary Nailing. |
| NCT05722002 CARES | HUM00215416 CER-2021C1-22398 | Ph 4 | recruiting | Comparing Analgesic Regimen Effectiveness and Safety for Surgery (CARES) Trial |
| NCT04629248 MAJESTY | WA41937 2020-003233-38, 2023-506525-11-00 | Ph 3 | active not recruiting | A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy |
| NCT03759028 | IRB# 18-001158 | Ph 4 | recruiting | Supracondylar Post-Operative Pain Study |
| NCT06214468 | 23-067/2026659-2 | Ph 1 | completed | Protective Effect of Nicotinamide Riboside Against Acetaminophen Toxicity |
| NCT06187584 results posted | STUDY00000286 | Ph 4 | completed | Supracondylar Humerus Fracture (SCHF) Post-Op Study Between Opioid and Non-Opioid Pain Management |
| NCT07502001 | HDM1005-104 | Ph 1 | not yet recruiting | Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin |
| NCT04268498 ADVANCE | 20201316 2019-001645-41, 19-339 | Ph 2 | active not recruiting | A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma |
| NCT03818932 results posted | 123192 | Ph 2, Ph 3 | completed | Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction |
| NCT03258593 results posted | 170157 17-C-0157 | Ph 1 | completed | Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) |
| NCT04459117 TREOCAPA | C19-29 2019-004297-26 | Ph 2, Ph 3 | completed | Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen |
| NCT05896228 Iber-KDd | 20230227 | Ph 2 | recruiting | Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma |
| NCT02858310 results posted | 160154 16-C-0154 | Ph 1, Ph 2 | completed | E7 TCR T Cells for Human Papillomavirus-Associated Cancers |
| NCT06671002 CARES for Kids | HUM00252793 BPS-2023C1-32147 | Ph 4 | recruiting | Comparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids Trial |
| NCT03974932 results posted | HTX-011-306 | Ph 3 | completed | Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen |
| NCT03695367 results posted | HTX-011-215 | Ph 2 | completed | Phase 2 Herniorrhaphy Study for Opioid Elimination |
| NCT07429032 | 20230012 | Ph 1 | completed | The Effect of AMG 133 on Gastric Emptying |
| NCT06356571 SubQSA | LPS18183 U1111-1298-7348 | Ph 2 | recruiting | A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma |
| NCT06994442 OPTICOM | 24-12028276 U01HD116260 | Ph 3 | recruiting | Optimizing Pain Treatment in Children On Mechanical Ventilation |
| NCT04224558 | Pro00051458 | Ph 1, Ph 2 | recruiting | Stem Cell Transplantation in Crohn's Disease |
| NCT03913559 | INOMRD NCI-2019-01062 | Ph 2 | terminated | Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia |
| NCT07101445 | STUDY00008909 NCI-2025-03018, STUDY00008909 | Ph 4 | recruiting | Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial |
| NCT05488847 results posted | 15592 | Ph 4 | active not recruiting | Opioid-Free Pain Protocol After Shoulder Arthroplasty |
| NCT05640674 results posted | 52475 | Ph 4 | terminated | Post-operative Pain Management in Children With Supracondylar Humerus Fractures |
| NCT04918147 results posted | DAIT AIG01 UM1AI144298, NIAID CRMS ID#: 38708 | Ph 2 | terminated | Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) |
| NCT01391962 results posted | 110200 11-C-0200 | Ph 2 | completed | Sunitinib or Cediranib for Alveolar Soft Part Sarcoma |
| NCT04681105 | 20472 NCI-2020-08118, 20472 | Ph 1 | completed | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies |
| NCT06997016 | Baylor IRB #025-220 | Ph 4 | enrolling by invitation | Enhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients |
| NCT02797522 results posted | ARC5211001 | Ph 1 | terminated | A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB) |
| NCT05211336 results posted | 10000516 000516-C | Ph 1 | active not recruiting | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System |
| NCT03978767 PANDA | 201901202 | Ph 2 | completed | Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial |
| NCT05704049 IZALCO | ACT17453 U1111-1280-5090, 2023-508870-27 | Ph 2 | active not recruiting | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma |
| NCT05603832 | 100-CIP02-P | Ph 3 | completed | A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement |
| NCT04270409 | EFC15992 U1111-1222-7068, 2023-507419-37 | Ph 3 | active not recruiting | Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma |
Showing 50 of 250 trials
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
OXYCODONE AND ACETAMINOPHEN FDA Label Details
Indications & Usage
FDA Label (PDF)Oxycodone and Acetaminophen Tablets is indicated for the relief of moderate to moderately severe pain.
WARNING Hepatotoxicity Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one a...
Track OXYCODONE AND ACETAMINOPHEN with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.